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Abstract 
In this study the effect of the A~ agonist 2-chloro-N6-cyclopentyladenosine (CCPA) on bis(l,3-diethylthiobarbituric ac d)trimethine 
oxonol (bisoxonol)-monitored membrane potential in cerebrocortical nerve endings was evaluated. CCPA (30, 100 and 300/xM) caused a
dose-dependent decrease of high K ' -  and veratridine-induced membrane depolarization. This decrease was counteracted by the 
Arspecific antagonist 1,3-dipropyl-8-cyclopentylxanthine (DPCPX) (30-100 /zM). On the contrary, the A 2 receptor antagonist 
9-chloro-2-(2-furanyl)-5,6-dihydro-l,2,4-triazolol-[1,5-c]quinazoline-5-imine (CGS 15943) was unable to interfere with the lowering 
effect exerted by CCPA (100 ~M) on K---elicited membrane depolarization. Finally, the A 2 receptor agonist 2-[p-(2-carboxy- 
ethyl)phenethylamine]-5'-N-ethylcarboxamidoadenosine (CGS 21680) did not induce any modification of K'-induced membrane depolar- 
ization. The results of the present study suggest that K---induced membrane depolarization i  cerebrocortical brain nerve endings may be 
modulated by A~ receptors. 
Kerwords: A ~ agonist activity; Agonist; Chlorocyclopentyladenosine; Membrane potential; Bisoxonol monitoring; Potassium ion; Cerebrocortical nerve 
ending 
1. Introduction 
There is considerable evidence that adenosine acts as an 
inhibitory modulator of neuronal activity in the CNS. In 
fact, it has been shown that it inhibits neuronal firing rates, 
synaptic transmission and neurotransmitter release [1,2]. 
Adenosine exerts its modulatory activity by acting on 
receptors which were initially classified into two subtypes, 
termed A l and A 2, on the basis of their ability to inhibit or 
stimulate cAMP formation [3]. The advent of radioactive 
ligands for adenosine binding sites allowed a more defini- 
tive receptor classification based on agonist affinity. By 
means of this methodology it has been shown that the A~ 
receptors are widely distributed throughout several regions 
of the brain [4]. By contrast, A 2 high-affinity binding sites 
have been found only in some brain areas such as striatum, 
Abbreviations: CCPA, 2-chloro-N6-cyclopentyladenosine; DPCPX, 
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olfactory tubercle and nucleus accumbens [5,6], although, 
more recently, a subpopulation of A 2 receptor sites at low 
affinity, that displays a wide distribution throughout he 
brain, has been characterized [7]. 
The activation of A l receptors eems to be responsible 
for the inhibition of neurotransmitter release [8]. It has 
been suggested that this effect may be due to a blockade of 
Ca 2+ influx into nerve terminals [9]. Since a condition of 
membrane hyperpolarization may also lead to an inhibition 
of neurotransmitter r lease, it appeared of interest o evalu- 
ate the activity of 2-chloro-N6-cyclopentyladenosine 
(CCPA), an adenosine derivative possessing high affinity 
for A~ receptors [10], on bisoxonol-monitored membrane 
depolarization i duced by high K + concentrations or vera- 
tridine in cerebrocortical synaptosomes. In order to verify 
the specificity of the effect of CCPA on K*-induced 
membrane depolarization, its action was evaluated in the 
presence of the specific A l receptor antagonist, 1,3-dipro- 
pyl-8-cyclopentylxanthine (DPCPX) [11]. Furthermore, to 
rule out any effect of CCPA on A 2 receptors, 9-chloro-2- 
(2-furanyl)-5,6-dihydro- 1,2,4-triazolol[ 1,5-c]quinazoline-5- 
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imine (CGS 15943) [12], a selective antagonist of these 
receptor subtypes, was tested on CCPA-induced changes in 
K+-elicited membrane depolarization. In addition, the ef- 
fect of the specific agonist of A 2 receptors, 2-[ p-(2- 
carboxyethyl)phenethylamine]-5'-N-ethylcarboxamidoaden- 
osine (CGS 21680) [13], was also examined. 
2. Materials and methods 
2.1. Synaptosomal preparation 
Synaptosomal fractions from brain cortex of adult male 
Wistar rats (150-200 g body wt.) were prepared according 
to the procedure of Dunkley et al. [14], using a discontinu- 
ous Percoll gradient. Briefly, rats were killed by decapita- 
tion and the brains were removed and kept on ice. Brain 
cortex was dissected by means of a fine lancet. Tissue was 
then homogenized using a Teflon-glass homogenizer in 9 
ml/g tissue of cold sucrose medium, whose composition 
was (in mM): 320 sucrose, 1 EDTA, 0.25 DTT, adjusted to 
pH 7.4 with 1 M NaOH. The homogenate was centrifuged 
for 10 min at 1000 X g at 4°C. The supernatant (S1) was 
diluted to 14 ml /g of starting tissue with sucrose medium, 
and 2 ml of S l were layered on the top of a tube containing 
four different Percoll concentrations (from the bottom (in 
v/v): 23%, 15%, 10% and 3% Percoll sucrose media), 
prepared using a peristaltic pump in order to achieve flat 
interfaces among the solutions at different Percoll concen- 
trations. The gradients were then placed in a Sorvall RCSB 
superspeed centrifuge and spun at 4°C for 5 min at 32 000 
× g in an SS-34 rotor. After centrifugation, the fraction at 
the interface between the 23% and 15% Percoll layers 
(fraction 4), as described by Dunkley et al. [14], which is 
highly enriched in viable synaptosomes [14] and which 
was examined in the present study by electron microscopy 
(Fig. 1), was removed and diluted 5-times in a solution 
containing (in raM): 125 NaC1, 2.5 KCI, 1.2 KH2PO 4. 1.2 
MgSO 4, 5 NaHCO 3, 25 Hepes, 6 glucose (pH 7.4). 
Diluted synaptosomes were centrifuged two times at 
15 000 × g for 15 rain at 4°C, in order to remove Percoll. 
The final pellet was resuspended in a medium containing 
(in mM): 145 NaC1, 5 KCI, 1.2 MgC12, 10 glucose, 10 
Hepes (pH 7.4) (standard Ca2+-free medium), at a protein 
concentration of 3-10 mg of synaptosomal proteins per 
ml, and immediately used for the following experimental 
procedures. 
2.2. Determination of synaptosomal membrane potential 
variations 
The lipophilic anion bisoxonol, which has been used to 
monitor membrane potential changes in several cell types 
[15-17] was added, in a concentration of 300 nM from a 
stock solution of 150 /xM in DMSO, to the quartz cuvette 
of the spectrofluorimeter containing 2 ml of prewarmed 
medium. Fluorescence intensity of the dye was recorded at 
an excitation and emission wavelengths of 540 and 580 
nm, respectively (5 nm slits for both excitation and emis- 
sion wavelengths). After 1 min from the addition of bisox- 
onol, 40-50 /xg of synaptosomal proteins were pipetted 
into the cuvette. Bisoxonol fluorescence intensity varia- 
tions were not converted into absolute membrane potential 
values, since the valinomycin ullpoint method [15] could 
Fig. I. Synaptosomal preparation image obtained by electron microscopy. 
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not be applied due to the formation of complexes between 
the lipophilic anion bisoxonol and the positively charged 
molecule of valinomycin. 
CCPA, DPCPX, CGS 21680 were dissolved in DMSO 
at the concentrations of 100, 25 and 100 and raM, respec- 
tively. CGS 15943 was dissolved in H20 at a concentra- 
tion of 5 raM. 
The same volume of solvent utilized to obtain the 
desired concentration of drugs under investigation did not 
induce any change of bisoxonol fluorescent intensity sig- 
nal. 
2.3. Protein determination 
Synaptosomal protein concentrations were determined 
by the method of Bradford [18]. 
2.4. Materials 
CCPA and DPCPX were purchased by R.B.I. (Natick, 
MA, USA). CGS 15943 and CGS 21680 were a gift from 
CIBA Geigy (Summit, NJ, USA), Bisoxonol was pur- 
chased from Molecular Probes (Eugene, OR, USA). 
3. Results 
3.1. Effect of different concentrations of CCPA on K +-in- 
duced changes of bisoxonol-monitored synaptosomal mem- 
brane potential 
When synaptosomes, incubated in the standard medium, 
were exposed to increasing concentrations of K + ions, a 
dose-related depolarization, monitored by the increase of 
bisoxonol fluorescence mission, was observed (Fig. 2). 
The addition in sequence to the incubation medium of 
increasing concentrations (30-100 and 300 /zM) of the A~ 
receptor agonist CCPA caused a dose-dependent reversion 
of 35 mM K+-induced membrane depolarization (Fig. 3). 
When CCPA (100/~M) was added to synaptosomal prepa- 
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Fig. 2. Dose-effect of K+-induced synaptosomal membrane depolariza- 
tion. After isolation, synaptosomes were resuspended in a standard 
Ca-~+-free medium and subjected to a 30 rain incubation at 37°C. After 
this period, they were pelleted, resuspended in the same buffer and kept 
on ice until their experimental use. Just prior to use, 4-5/zl  of synaptoso- 
real resuspension (40-50/zg of synaptosomal protein) was pipetted in the 
spectrofluorimeter cuvette containing 2 ml of a prewarmed 1 mM Ca 2+- 
containing medium plus 300 nM bisoxonol. Fluorescence emission of the 
dye was recorded for at least 90 s and, in the absence of any other 
experimental manipulation, it remained stable for the whole duration of 
the recording. After 90 s, as indicated by the arrow. 35 mM K + was 
added to the synaptosomes. After a further period, synaptosomes were 
exposed to 50 mM K +, as indicated by the second arrow. 110 s later 90 
mM K + was added to the medium. The results are expressed as arbitrary 
units of bisoxonol fluorescence intensity, due to the absence of a repro- 
ducible calibration procedure for the fluorescent dye, as described in the 
Materials and methods ection. In all figures, each trace is representative 
of at least three similar independent experiments. 
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Fig. 3. Effect of increasing concentrations of CCPA on K+-induced 
synaptosomal membrane depolarization. The experiment was performed 
as described in the legend for Fig. 2. Synaptosomes were first exposed to 
35 mM K + and then to increasing concentrations of CCPA which were 
added to the medium where indicated by the arrows. 
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Fig. 4. Effect of CCPA on 35 + mM K -plus gramicidin-induced depolarization. The experiment was performed as described in the legend of Fig. 2.35 mM 
K +, 5 /~M gramicidin and 100 /zM CCPA were added to the medium, where indicated by the arrows. 
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rations after 35 mM K ÷ plus gramicidin (which equili- 
brates internal and external K + ion concentrations), it 
failed to induce any change of membrane potential (Fig. 
4), suggesting that any nonspecific optical changes elicited 
by the compound can be excluded. 
/xM CCPA. DPCPX by itself did not induce any change of 
bisoxonol fluorescence increase elicited by 35 mM K ÷, 
whereas it counteracted, in a dose-dependent way, the 
decrease induced by CCPA of K+-elicited depolarization 
(Fig. 6B and 6C), respectively. 
3.2. Effect of CCPA on membrane potential titration per- 
formed with increasing concentrations of K + 
If CCPA (100 /xM) was added to cerebrocortical nerve 
endings before a titration with increasing concentrations of
K + (35, 50 and 90 raM) followed by gramicidin (5 /zM), 
the mean of the observed optical changes after addition of 
each K + concentration and gramicidin was not significant 
from that found in absence of the compound under investi- 
gation (data not shown). 
3.3. Effect of different concentrations of CCPA on veratri- 
dine-induced changes in membrane potential 
When synaptosomes were exposed to 30 ~M veratri- 
dine, a membrane depolarization was observed. Increasing 
concentrations of CCPA induced a dose-dependent rever- 
sion of veratridine-elicited membrane depolarization (Fig. 
5). When CCPA (100 ktM) was added to cerebrocortical 
nerve endings before veratridine (30 /xM), it blocked 
veratridine-induced depolarization (data not shown). 
3.4. Effect of the A 1 receptor antagonist DPCPX on 
CCPA-induced reversion of membrane depolarization 
elicited by 35 mM K + 
3.5. Lack of effect of the A: receptor antagonist CGS 
15943 on CCPA- induced inhibition of membrane depolar- 
ization elicited by 35 mM K + 
In order to exclude the possibility that CCPA might 
counteract membrane depolarization elicited by 35 mM 
K + through an unspecific interaction with A 2, the specific 
A 2 receptor antagonist CGS 15943 was added to the 
incubation medium before 35 mM K ÷ and CCPA. CGS 
15943 (1 /zM) was unable to interfere with the lowering 
effect exerted by CCPA (100 /xM) on K+-elicited mem- 
brane depolarization (Fig. 7). 
3.6. Lack of effect of the A: receptor agonist CGS 21680 
on membrane depolarization i duced by 35 mM K + 
In order to further support the hypothesis that the 
stimulation of A 2 receptors does not exert an inhibitory 
effect on K+-induced membrane depolarization, CGS 
21680, a specific agonist of A 2 receptor subtype, was 
added to the incubation medium 1 min after 35 mM K +. 
This compound, at the concentration of 100 /zM, did not 
induce any modification of K+-induced membrane depo- 
larization (Fig. 8). 
CCPA (100 /zM) added to the incubation medium 1 
min after 35 mM K + caused a decrease of K+-induced 
depolarization that was of 3 arbitrary units of bisoxonol 
fluorescence intensity (Fig. 6A). In order to evaluate the 
specificity of CCPA-induced reversion of membrane depo- 
larization elicited by 35 mM K +, the A t receptor antago- 
nist DPCPX (30-100 /xM) was added to incubation 
medium before the exposure to 35 mM K + and to 100 
4. Discussion 
The results of the present study showed that CCPA, a 
selective agonist of A ~ receptor, is able to cause a dose-de- 
pendent inhibition of membrane depolarization i duced by 
35 mM K + and veratridine in cortical brain synaptosomes. 
It has been reported that this adenosine derivative pos- 
sesses a selectivity versus A~ receptor subtype that is 
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Fig. 5. Effect of increasing concentrations of CCPA on veratridine-induced membrane synaptosomal depolarization. The experiment was performed as 
described in the legend for Fig. 2. Synaptosomes were first exposed to 30 p,M veratridine and then to increasing concentrations of CCPA, which was 
added to the medium where indicated by the arrows. 
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Fig. 6. Effect of different concentrations of DPCPX on CCPA-induced ecrease of membrane depolarization elicited by 35 mM K +. The experiment was 
performed as described in the legend for Fig. 2. In (A), 35 mM K + was added to the medium after 100 s, as indicated by the arrow. After a further period 
of 55 s, synaptosomes were exposed to 100 /xM CCPA. DPCPX (30 and 100 /zM) was added to the medium at the beginning of the experiment, as 
indicated by the arrow. 1 min later, synaptosomes were exposed to 35 mM K ÷ (second arrow), 100/xM CCPA was added to the incubation medium (third 
arrow) after a further period of 90 and 120 s ((B) and (C), respectively). DPCPX (30 and 100 ~M), caused a reversion of CCPA-elicited inhibition of 
K+-induced membrane depolarization of 33 and 70%, respectively. The means of the fluorescence arbitrary unit values (6 n for each experimental group) 
obtained with 100/xM CCPA following K + addition in the presence of 30 and 100/xM DPCPX were significantly different from the mean of the values 
obtained with 100 /zM CCPA following K ÷ addition in the absence of DPCPX (p  _< 0.05 ANOVA followed by Newman Keul's test). 
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Fig. 7. CCPA-induced ecrease of membrane depolarization elicited by 
35 mM K + is unaffected by the A 2 receptor antagonist CGS 15943. The 
experiment was performed as described in the legend of Fig. 2. CGS 
15943 was added into the medium when indicated by the arrow. After I 
rain synaptosomes were exposed to 35 mM K +, as indicated by the 
second arrow. 75 s later 100 /xM CCPA was pipetted into the couvette 
(third arrow). 
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Fig. 8. Lack of effect of the A 2 receptor agonist CGS 21680 on 
membrane depolarization induced by 35 mM K +. The experiment was 
performed as described in the legend of Fig. 2. Synaptosomes were 
exposed to 35 mM K + where indicated by the arrow. 100 ~,M CGS 
21680 was added to the incubation medium, when indicated by the 
second arrow. 
modulation of membrane potential following K + exposure 
since CGS 21680, a compound widely used as A 2 agonist 
[13], did not induce any change of membrane depolariza- 
tion elicited by high concentrations of K +. 
At the present time the mechanisms underlying the 
capability of CCPA to reverse veratridine and high K+-in -
duced depolarization are unknown; however, since the 
removal of CI ions did not prevent he CCPA-induced 
hyperpolarization (data not shown), the reversal of mem- 
brane potential induced by CCPA does not involve an 
increase in CI ion permeability, as occurs in other tissue 
preparations [4,20]. Furthermore, the fact that CCPA was 
able to reduce high-K +-clamped membrane potential depo- 
larization suggests that it is acting by a mechanism other 
than the activation of K + channels. Whatever mechanism 
is activated by CCPA, it should be operating also in 
conditions of veratridine-induced depolarization, whereas a
blockade of Na + channels that could explain this effect 
does not seem likely, since it does not justify CCPA-in- 
duced reduction of K+-elicited membrane potential depo- 
larization. 
It could be observed that the concentrations of CCPA 
used in the present study were quite high if one considers 
that its K i versus A] receptors is 0.4 nM [10] and 
therefore its effect on K + and veratridine-induced mem- 
brane depolarization cannot be considered very specific. 
However, this observation does not seem to be in line with 
the findings showing that the effect of CCPA on K+-in -
duced membrane depolarization was dose-dependently re-
versed by the specific A~ receptor antagonist DPCPX, 
whereas the selective A 2 antagonist CGS 15943 was inef- 
fective in antagonizing the effect of CCPA. 
In conclusion, the results of the present study suggest 
that K+-induced membrane depolarization i cerebrocorti- 
cal brain synaptosomes may be modulated by A~ receptors 
and therefore this model may be proposed as a reliable and 
suitable tool to evaluate the activity of A ~ agonists. 
almost 10000-fold higher than versus A 2 subtype [10]. 
Therefore, it is reasonable to hypothesize that the effect of 
CCPA on high K + and veratridine-induced membrane 
depolarization is due to the stimulation of the A 1 subtype 
of receptor. This hypothesis eems to be supported by the 
findings showing that the effect of CCPA on K +- induced 
membrane depolarization was antagonized by the specific 
A~ antagonist, DPCPX. This compound can be considered 
a selective A l antagonist, since its A2/A~ ratio of affinity 
is almost 700 [11]. Moreover, it has been recently sug- 
gested that DPCPX can be used as probe for in vivo 
localization of brain A~ receptors [19]. Further support o 
the view that the inhibition exerted by CCPA on K+-in -
duced depolarization is due to a stimulation of A~ recep- 
tors is represented by the results showing that the A 2 
antagonist, CGS 15943, [12] was unable to antagonize the 
effect of CCPA on K+-induced membrane depolarization. 
In addition, A 2 receptors do not seem to be involved in the 
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